Replies to post #40 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

RNVC’s pro forma cash at 9/30/15—including net proceeds from the Nov2009 financing—was ~$271M; guidance for cash at 12/31/15 is >$245M, implying an operating cash burn of as much as $36M in 4Q15:

#msg-118372406